
Nuvation Bio (NUVB) Stock Forecast & Price Target
Nuvation Bio (NUVB) Analyst Ratings
Bulls say
Nuvation Bio is expected to continue its robust growth with a diversified pipeline, including the recent acquisition of Japan rights to safusidenib, and cash on hand to fund operations in the near term. The company has a differentiated product in taletrectinib, with potential for fast-track approval due to its potential in treating ROS1+ NSCLC, and promising PRO data for its TRUST-IV study. There are risks to consider, including clinical trial delays and potential competition, but the company's current valuation presents an attractive opportunity for investors.
Bears say
Nuvation Bio is expected to generate revenue primarily from out-licensing collaborative agreements, with a specific focus on its product candidate, taletrectinib, for the treatment of ROS1+ non-small cell lung cancer (NSCLC). However, the company's quarterly new patient starts in 1Q26 only accounted for ~13% penetration of the estimated ~3,000 newly diagnosed ROS1+ NSCLC patients annually, indicating slower than expected adoption trends and potential competition from other therapies. Furthermore, potential risks include delays in trial enrollment and regulatory approvals, and the emergence of better-than-expected competitor products, which may hinder the company's ability to meet its revenue projections.
This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.
Nuvation Bio (NUVB) Analyst Forecast & Price Prediction
Start investing in Nuvation Bio (NUVB)
Order type
Buy in
Order amount
Est. shares
0 shares